Lilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bn
Next issueIssue 16 · Tue 29 Sep 

Trials

2025-524973-17-00

EU Clinical Trials Information System

Trial ID
T-ctis-2025-524973-17-00
Registry
EU Clinical Trials Information System
CTIS number
2025-524973-17-00
Asset
brenipatide (LY3537031)
Sponsor, as registered
Eli Lilly & Co.
Phase
Therapeutic exploratory (Phase II)
Indication
Irritable Bowel Syndrome Diarrhea
Status
Authorised
Primary completion
CTIS does not publish one.
Member states concerned
Belgium, Germany, Poland, Spain
Sites
31

Member states whose regulator has a decision on this trial.

euclinicaltrials.euctis registryverified 2026-08-31

Notes on the record

countries is memberStatesConcerned, i.e. every member state the trial is filed in; site_count sums trialSites across authorised Part II sections. primary_completion_date is EMPTY because CTIS does not publish a primary completion date; it is not unknown, it is not a field the registry has. Per-state authorisation is NOT recorded: mscPublicStatusCode takes values [2] on this record and the registry publishes no key for them, so decoding it would be a guess.

Company

Through brenipatide (LY3537031): Lilly

Cited in

Issues quoting 2025-524973-17-00 in their own text.